Table 4

Cause-specific HRs and subdistribution HRs of the revascularisation versus medical therapy difference

ACDCD/MI
CSHRp ValueSDHRp ValueCSHRp ValueSDHRp Value
(a) Patients with normal MPS
Univariate analysis3.850.0013.420.00215.44<0.000114.09<0.0001
Adjusted for clinical variables
 Age3.220.0033.120.00512.93<0.000111.75<0.0001
 Gender3.580.0013.170.00315.11<0.000113.85<0.0001
 Age, gender2.890.0072.800.0112.37<0.000111.26<0.0001
 DM3.810.0013.390.00215.30<0.000113.99<0.0001
 Known CAD3.760.0013.470.00213.04<0.000112.29<0.0001
 Previous MI3.97<0.00013.520.00212.76<0.000112.01<0.0001
 Previous PCI4.27<0.00013.870.00114.42<0.000113.45<0.0001
 CAD category*3.710.0013.450.00313.02<0.000112.26<0.0001
 CAD category*, previous MI3.680.0013.420.00412.87<0.000112.48<0.0001
 CAD category*, previous MI, aspirin, beta blocker, lipid lowering4.22<0.00013.810.00111.86<0.000111.43<0.0001
 Gender, CAD category*, previous MI, aspirin, beta blocker, lipid lowering4.080.0013.660.00211.76<0.000111.34<0.0001
Adjusted for angiographic variables
 CCS score (n=223/115)4.270.0033.770.00612.06<0.000111.03<0.0001
 Number of stenotic vessels (n=210/108)4.620.0054.520.0069.190.0019.280.001
 CCS score, number of stenotic vessels (n=210/108)4.520.0074.180.0079.890.0019.490.002
Adjusted for scintigraphic variables
 At-rest LVEF (n=648/147)2.870.082.970.0812.78<0.000112.86<0.0001
 Post-stress LVEF (n=687/123)2.700.092.800.1012.74<0.000112.93<0.0001
Adjusted for selected variables of all types
 Gender, CAD category*, previous MI, aspirin, beta blocker, lipid lowering, CCS score (n=223/115)4.550.0043.480.00929.29<0.000126.69<0.0001
 Gender, CAD category*, previous MI, aspirin, beta blocker, lipid lowering, number of stenotic vessels (n=210/108)4.300.023.790.0311.700.00111.800.001
 Gender, CAD category*, previous MI, aspirin, beta blocker, lipid lowering, CCS score, number of stenotic vessels (n=210/108)4.140.023.310.0620.860.00120.230.001